&lt;i&gt;Epimedium&lt;/i&gt; attenuates neuroinflammation and ameliorates Alzheimer's disease through a KAT2B-dependent mechanism. This evidence concerns the gene KAT2B and early-onset autosomal dominant Alzheimer disease.